PLURNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30
Pluri Inc.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 10, 2026
$0.85−0.08 (-8.58%)
Close on Oct 19, 2026
- Market cap
- $9.08M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2026
Gross margin
44.6%
Operating margin
-2454.5%
Net margin
-2344.6%
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -24.0% | +52.4% | – | -9.8% | |
| Gross profit | -30.7% | +17.7% | – | -16.5% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | -81.3% | -88.1% | 159.5% | |
| Return on assets | -66.6% | -62.7% | -75.0% | |
| Current ratio | 5.36 | 5.85 | 0.27 | |
| Interest coverage | – | -649.0× | -26.8× | |
| Capex to revenue | – | – | 62.3% | |
| Diluted shares | 1M | 4M | 10M |
Where the cash went
Fiscal 2022 to 2026, five years combined
Pluri generated $115.18M from operations and spent $3.12M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$115.18M
Used
$3.12M
Capital expenditure$3.12M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-2344.6%
×Asset turnover0.03×
×Equity multiplier-2.13×
=Return on equity, FY2026159.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | -2344.6% | 0.03× | -2.13× | 159.5% |
| FY2025 | -1690.3% | 0.03× | -11.59× | 669.5% |
| FY2024 | -6407.4% | 0.01× | 6.72× | -310.6% |
| FY2023 | -9867.9% | 0.00× | 2.74× | -130.5% |
| FY2022 | -17624.8% | 0.00× | 1.85× | -94.6% |
| FY2020 | -126747.8% | 0.00× | 1.24× | -74.8% |
| FY2019 | -65383.3% | 0.00× | 1.40× | -140.3% |
| FY2018 | -52252.0% | 0.00× | 1.30× | -88.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
1of 8 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero-$23.82M
- Cash generatingOperating cash flow above zero-$19.59M
- Return on assets improvedROA up on the prior year-57.1% → -61.6%
- Earnings backed by cashOperating cash flow above net income-$19.59M vs -$23.82M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.68 → 0.27
- No dilutionShare count did not rise6M → 10M
- Gross margin improvedGross margin up on the prior year48.95% → 44.59%
- More efficientAsset turnover rose0.03 → 0.03